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Objectives: A review of patients requiring lifelong antibiotics to control, rather than cure, infection was
performed [‘palliative outpatient parenteral antibiotic therapy (OPAT)’]. This was to evaluate emerging themes
and complications. The aim was to aid in the management of such patients.
Methods: A retrospective review of the OPAT database over 5 years (2013–17) was performed. Of the 1438
patients, 9 were deemed to have received palliative OPAT.
Results: The palliative cohort represented 0.6% of the total number of patients on OPAT and 8.6% of the bed
days saved. Patients fell into two main groups: those with multiple comorbidities that precluded surgical man-
agement and those with a terminal condition. Both groups received IV antibiotics with no clear endpoint. The
themes to emerge were: patients often had multiple comorbidities with a high operative risk to control the
source of infection; a trial of no or oral antibiotics led to resurgence of the infection; vascular patients appeared
to tolerate long-term antibiotics well; and conversely, antibiotic side effects were a significant issue in others.
Patients with incurable cancer and a coincident infection can be given additional quality of life with the judicious
use of appropriate therapy.
Conclusions: There are significant issues surrounding antimicrobial stewardship in the palliative OPAT group
that should be considered. Excellent communication is required to deal with these often very complicated
patients. There are considerable gains to be made both for patients and the number of bed days saved. The small
number of patients accounted for a disproportionate number of bed days saved.
Introduction
Outpatient parenteral antibiotic therapy (OPAT) is a method for
delivering IV antimicrobials in the community or outpatient setting
as an alternative to inpatient care. Since first described in 1974 for
the management of paediatric patients with cystic fibrosis,1 OPAT
has demonstrated improvements in the quality of life for patients
for whom administration of IV antibiotics is their primary reason
for inpatient hospital care. It has also reduced the associated costs
of prolonged hospital admissions.2–5
In the UK, patient acceptance and clinical experience with OPAT
are increasing, becoming part of routine recommendations for
many chronic, subacute and acute infections. Principles and
practice of OPAT recommend that infections treated should have a
low probability of progression with a predictable response to ther-
apy and the outcome for patients should be a more rapid return to
normality, work or education.6 A small number of patients do not
meet these recommendations but still require lifelong OPAT as
part of palliative care. Although few in number, these patients
have required a considerable investment of time and resources
with regard to planning their antibiotic combinations and manag-
ing their conditions.
Recent good practice recommendations have acknowl-
edged palliation as a treatment aim.7 This paper aims to share
our experience in meeting the needs of this particular patient
group.
Methods
Our working definition of palliative OPAT refers to patients who require life-
long antibiotics to control rather than cure any infection. They are dis-
charged from hospital with the intention that the antibiotics continue
lifelong, although this has not always been possible. It is understood that if
the antibiotics are stopped then this will lead to resurgence of the underly-
ing infection.
The Nottingham University Hospitals NHS Trust OPAT service was estab-
lished in 2011 in the regional Infectious Diseases Unit, based in a large
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teaching hospital. In the time frame reviewed, the service followed the
Good Practice Recommendations 2012 standard of care with a multidiscip-
linary team approach comprising microbiologists, infectious diseases
physicians, a specialist nursing team and an antimicrobial pharmacist.8
The service uses two models of antibiotic delivery. The first takes place at
an outpatient ‘infusion centre’ in the hospital and the second is patient/
carer or nurse administration in the patient’s home. The latter requires
weekly visits to the outpatient clinic as per UK national good practice rec-
ommendations. There is 24 h access for admission, as necessary, for all
OPAT patients.
The database was reviewed retrospectively for those patients who had
received prolonged antibiotics and those with a diagnosis of palliative con-
ditions (see Tables 1 and 2). Over the 5 year period (2013–17), nine patients
were identified who commenced OPAT with no expectation of a curative
outcome. Patients who received repeated cycles of OPAT for the same con-
dition (e.g. bronchiectasis) were excluded. During this period the OPAT data-
base changed and, if it was not possible to clarify the length of time
antibiotics were given, the clinical letters were reviewed to discover the ap-
propriate data.
Ethics
This work was deemed to be a service evaluation of palliative patients to
help inform future care of this cohort and therefore, in line with NHS Health
Research Authority guidelines, ethics approval was not required.9
Results
During a 5 year period, we identified nine patients who met our
definition of palliative OPAT. The number of bed days saved for this
small number of patients was 3406, reflecting the length of time
that patients can tolerate this form of management. The total
number of OPAT patients during this period was 1438. The pallia-
tive cohort represented 0.6% of the total number of patients and
8.6% of the bed days saved.
Informal qualitative review of patient and infection characteris-
tics identified two distinct groups and six recurrent themes.
Two groups of patients were identified. In the first group
(Table 1) OPAT was used for the primary condition where there
were no oral options or definitive surgical treatments possible. This
group was made up of patients with vascular graft infections and
pelvic abscesses. The second group (Table 2) consisted of patients
with a terminal condition where OPAT was used to treat coincident
infections. Common themes to emerge on review of all patients
were: (i) the presence of multiple comorbidities; (ii) the underlying
condition was inoperable, often due to high anaesthetic risk; (iii) a
trial of IV antibiotics with or without oral antibiotics (if resistance
suggested that this was an option) led to relapse of the infection;
(iv) those who experienced multiple side effects with antibiotics
struggled with prolonged courses; (v) vascular patients with deep-
seated infections seemed to tolerate long-term antibiotics well;
and (vi) patients with incurable cancer and a coincident infection
can be given additional quality of life with the judicious use of ap-
propriate therapy.
Patient case studies
We present four case studies that are representative of the
patients who have commenced long-term OPAT to illustrate the
issues and learning points.
Patient 1
An 81-year-old man had an elective repair of an abdominal aortic
aneurysm in 2008. The procedure was complicated by infection
and bleeding. He relapsed on oral antibiotics multiple times and, in
2013, was attending the vascular ward on a daily basis for IV anti-
biotics. He was referred to OPAT. He learnt to administer his own
antibiotics using prefilled devices and was able to go on holiday.
He died some years later of unrelated causes. OPAT allowed him to
regain his independence and improved the quality of his life. This
was our first patient on palliative OPAT and this relative success
story made us more receptive to other cases.
Patient 4
A 78-year-old woman had a deep pelvic collection of uncertain ori-
gin that was inoperable due to her comorbidities. She had had six
inpatient admissions over the previous 6 months for sepsis. She
had been treated with short courses of IV antibiotics and had
relapsed on oral regimens. After much discussion she was dis-
charged on OPAT, on the understanding that this would be lifelong
and with the intention of allowing her to remain at home. She
managed to complete 8 weeks of OPAT before significant
antibiotic-related side effects of nausea, vomiting and diarrhoea
precluded continuation. Side effects severely impacted on her
quality of life. Cessation of treatment required extensive conversa-
tions with the patient, the GP and the family to ensure that all
understood the implications of stopping antibiotics and the impact
that the antibiotics were having on the patient’s quality of life.
OPAT was intended to provide better quality of life and prevent
hospital admission. In addition, there was difficulty gaining blood
on a weekly basis for monitoring. This led to concerns regarding
the balance between side effects and the actual benefit of treat-
ment. OPAT failure led to clear end-of-life discussions that involved
the patient and her family and prevented further hospital admis-
sions. The balance between suppression of infection and manage-
able side effects is important to acknowledge and sometimes the
right decision is to stop treatment.
Patient 7
A 60-year-old man presented with a haemorrhagic cerebral in-
farct. During the course of his hospital admission he developed pul-
monary emboli requiring the insertion of an inferior vena cava
(IVC) filter. He subsequently developed MRSA sepsis secondary to
an infected wound on his foot. He was readmitted with discitis felt
to be secondary to MRSA. The IVC filter could not be removed. After
a full course of treatment, he relapsed with concern that the clot in
his IVC filter was chronically infected. The MRSA was multi-
resistant and attempts at suppression with the limited choice of
oral antibiotics failed due to side effects. OPAT allowed him to be
discharged to spend the rest of his life nearer his family and out of
hospital. The challenges of managing a multi-resistant bacterial in-
fection in a community setting were a learning process for all
involved.
Patient 8
A 70-year-old man was diagnosed with AML in July 2017. This
proved refractory to treatment and he was maintained on regular
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blood and platelet transfusions. He had a neutrophil count of zero
despite regular granulocyte colony stimulating factor (GCSF).
In September 2017, he developed a CoNS infection in a previous
total knee replacement. Surgery was felt to be too risky due to his
profound pancytopenia and he was commenced on teicoplanin. In
November 2017, his knee became more painful and swollen.
Table 1. Patients who had infection with an inoperable source
Patient
number
Age at
start
(years) Pathology Microbiology
Antibiotics (IV) and
method of
administration
Time on
OPAT Comments Outcome
1 81 Infected aortic graft,
no procedure pos-
sible due to frailty,
responded to
ertapenem
Escherichia coli • Ertapenem 1 g once
a day to 500 mg
once a day
• Self-administration
38 months • Death unrelated to in-
fection after prolonged
decline
• Dose modification as
renal function declined
due to comorbidities
deceased
2 65 Infected aortic graft,
no curative proced-
ure possible
E. coli,
Enterococcus
faecium (VRE)
• Tigecycline 50 mg
twice a day
• Self-administered
32 months
continuing
Has required occasional
insertion of drain into
infected mass, decision
made clinically and as
CRP increases
alive
3 81 Infected aortic graft,
no curative proced-
ure possible
E. coli • Ertapenem 1 g once
a day
• OPAT clinic
11 months Relapsed on oral cipro-
floxacin, requiring
drainage in response to
clinical symptoms and
rising CRP
alive
4 78 Inoperable pelvic
abscess (too frail to
survive surgery due
to multiple
comorbidities)
Coliform,
Enterococcus
• Ceftriaxone 2 g once
a day (with oral
metronidazole)
• Followed by dapto-
mycin 500 mg once a
day and ertapenem
1 g once a day
• Nurse delivered
7 weeks Changed treatment due to
severe nausea, vomiting
and diarrhoea, then
stopped altogether as
unable to tolerate,
multiple discussions
with regard to implica-
tions of stopping requir-
ing MDT involvement:
remained alive 4 weeks
after stopping
treatment
deceased
5 79 Inoperable pelvic
abscess (too frail to
survive surgery due
to multiple
comorbidities)
E. coli, anaerobes,
Actinomyces,
Enterococcus
gallinarum,
Enterobacter
• Meropenem 500 mg
twice a day
• Nurse delivered
8 weeks Readmitted due to physic-
al decline and inability
to cope and decision
made to stop antibiotics
as unable to monitor
and concern that risks
were outweighing
benefits
deceased
6 75 Infected EVAR graft Nil grown but sep-
tic when off
treatment
• Daptomycin 400 mg
once a day
• Nurse delivered
4.5 months Failed initial finite IV and
then severe side effects
with oral antibiotics
before restarting IV
deceased
7 60 Discitis, infected clot in
immovable IVC filter,
vascular malforma-
tion and osteomye-
litis right leg
MRSA • Vancomycin 500 mg
to 1 g twice a day
dependent on
twice-weekly levels
• Nurse delivered
17 months MDR MRSA meant that
vancomycin was the
only viable option; death
due to intracerebral
haemorrhage
deceased
CRP, C-reactive protein; MDT, multidisciplinary team; EVAR, endovascular aneurysm repair.
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Repeat aspiration showed that the bacteria had become resistant
to teicoplanin. He was changed to daptomycin. He remained as an
outpatient, attending haematology regularly for appropriate
transfusions until his death in April 2018. OPAT kept him out of hos-
pital during the last months of his life. It reduced the amount of
pain he experienced and kept him mobile. This man had a very
engaged family who appreciated that the antibiotics were control-
ling rather than curing the infection due to the low neutrophil
count.
Discussion
We have identified nine patients seen by our service over a 5 year
period in whom the term palliative OPAT is appropriate. We have
presented four case studies that are representative of the patients
who have commenced palliative OPAT to illustrate issues and
learning points. In the small number of patients we have seen, a
range of themes emerged, as detailed earlier. Of note is the per-
centage of bed days saved (8.6%) compared with the percentage
of palliative patients represented on the OPAT database (0.6%).
Improved quality of life
The use of OPAT in patients with little or no expectation of a cura-
tive outcome is an uncommon but important component of the
care our unit provides. The use of OPAT for palliation as opposed to
cure is analogous to other end-of-life care arrangements for can-
cer and long-term conditions. The purpose of palliative care is to
improve a patient’s subjective well-being by holistic, multidisciplin-
ary and family- as well as patient-centred interventions.10 Home-
based palliative care has been found to produce greater improve-
ments in independence and security, while safeguarding patients’
entire life situation and increased quality of life when compared
with that of patients admitted to hospital.11,12 In our experience,
we have found that it has provided freedom from the require-
ments of hospital admission and provides patients and their fami-
lies time in their own environment to achieve as much quality of
life as possible. While the majority of patients receive daily nursing
input to administer the antibiotics, for some patients it has proven
possible to foster greater independence by training them to deliver
their own antibiotic therapy. With organization, we have also
arranged for a patient on lifelong OPAT to travel and have their first
UK holiday in years.
Communication
Communication is a key element of high quality in palliative care
and the scope and timing of discussions between patient, family,
clinicians and the discharging team are particularly important.13
Appropriate and timely discussion with the patient and the family
should start with the discharging team before OPAT is started. In
general, patients have expressed a preference for discussions
around end-of-life care and ‘do not resuscitate’ orders to occur in a
private, quiet place with the full attention of a physician who is
able to communicate their diagnosis, prognosis and treatment
options clearly. Patients appreciate the time to ask questions and
to be given information about how the diagnosis and treatment
will affect their life and these discussions should occur prior to
discharge.14,15 This discussion can then lead on to ensuring
patients have a realistic expectation of what OPAT can offer and
what it can and cannot achieve. In the future, we aim to increase
staff training to increase staff confidence in discussing palliative
and end-of-life care.
Palliative OPAT in our setting has been most successful when
there has been excellent liaison with the parent specialities who
need to understand the limitations of OPAT with regard to side
Table 2. Patients with a terminal condition where OPAT was used to treat coincident infection
Patient
number
Age at
start
(years) Pathology Microbiology
Antibiotics (IV) and
method of
administration
Time on
OPAT Comments Outcome
8 70 Infected TKR, fur-
ther procedures
unsafe due to
resistant AML
with persistent
neutrophil count
of zero
CoNS • Teicoplanin 800 mg
once a day initially
then daptomycin
500 mg once a day
due to resistance
• Family delivered
7 months Died due to underlying
illness
deceased
9 60 Sepsis on a
background of
metastatic
colorectal cancer
MSSA • Ceftriaxone 2 g once
a day then 24 h
flucloxacillin due to
relapse of sepsis sec-
ondary to infected
portacath
• Nurse delivered
19 days
in total
• Two admissions; although
short period on OPAT, this
allowed him time at home
with his family that he
would not otherwise have
had
• Flucloxacillin lower MIC
compared with third-
generation cephalosporins
for MSSA
deceased
TKR, total knee replacement.
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effects, logistics and the fact that a cure is not going to be possible.
Effective communication between healthcare providers, the
patient and the family is integral to optimal care.16 The patient’s
GP and potentially palliative care teams should also be involved, as
necessary, and the intricacies of this interaction should be
resolved, ideally before discharge. There should be clear documen-
tation of the aims of the treatment and a transparent declaration
of its limitations.
Monitoring on OPAT
In-depth conversations with the patient and family need to ad-
dress the pros and cons of prolonged use of antibiotics and plans
for monitoring must be clearly laid out. Patient 4 in Table 1 suffered
from severe side effects from antibiotics that required her to stop
antibiotics after much discussion. Patient 5 could not be monitored
weekly for side effects of antibiotics. A decision was made that we
could not continue with OPAT as there were concerns that the anti-
biotics would lead to her premature death. Both of these patients
had deep pelvic abscesses and comorbidities prevented surgical
treatment. Conversely, Patient 1 had been on OPAT for so long and
had remained stable that monitoring took place every 2 weeks.
Updated Good Practice Recommendations
When these data were collected, the Good Practice
Recommendations 20128 classed any death whilst on OPAT as a
failure of treatment and OPAT care. The recently published Good
Practice Recommendations 20197 acknowledge the need for indi-
vidualized treatment aims and categorizes palliation as a treat-
ment aim. In these circumstances, death is an expected outcome
rather than a failure and enabling a patient to stay at home during
their last days undoubtedly improves quality of life.
Antimicrobial stewardship
There are antimicrobial stewardship issues with regard to the pro-
longed use of antibiotics, namely those of antimicrobial resistance.
If antimicrobial resistance continues to increase, palliative
OPAT may become increasingly relevant as effective oral options
may not be available. Gram-negative infections are already a
source of major concern.17 In the patients described above we
have not managed untreatable infections but two of the cohort
did develop organisms that became more resistant and required
modification of their antibiotics, whereas another patient had no
oral options available. This remains a concern for future practice.
In addition, the role of antibiotics with a prolonged half-life can
play a pragmatic role. Teicoplanin has been used on a thrice-
weekly basis at other centres18 and this could lend itself to a long
course of treatment, as in osteomyelitis.19 Dalbavancin is licensed
for a maximum of two doses at weekly intervals. Off licence it has
been used with success on a longer-term basis.20 A reduced num-
ber of doses of antibiotic per week lends itself to outpatient treat-
ment. At present, data on efficacy and safety are limited.
An alternative method of reducing the frequency of administra-
tion is 24 h infusion of antibiotics. In our unit, this mode of delivery
is slowly increasing. Stability data are available for piperacillin/
tazobactam21 and flucloxacillin.22 We used this method of delivery
for flucloxacillin in a patient whose deep-seated MSSA infection
relapsed as soon as his initial treatment had finished. It was not
possible to remove the source of the infection. As the MIC of flu-
cloxacillin is considerably lower than that of the third-generation
cephalosporins for MSSA, this was felt to be a safer option.23
Future plans
We believe that palliative OPAT is a relevant use of OPAT resources
for the small number of patients to whom it is applicable. It can im-
prove quality of life as well as keeping patients at home when
resources are limited. We hope to encourage the use of OPAT in
such situations within the hospital environment so that more spe-
cialities are aware of the potential possibilities and also have an
understanding of the logistics involved in appropriate discharge. It
is essential that all areas of patient care have been adequately
addressed. We aim to focus on patient feedback to see how our
service could improve. We are also exploring increased liaison with
our palliative care teams to ensure that clear and swift pathways
of communication are in place to ensure holistic patient care is
delivered.
Conclusions
Palliative OPAT can be successful and lead to positive outcomes for
patients and their families. It should be planned with sympathetic,
frank and pragmatic conversations with all concerned. Our experi-
ence of this complex group of patients is that it can achieve consid-
erable gains with regard to quality of life for patients and their
families.
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